GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Rocket Pharmaceuticals
Rocket Pharmaceuticals is a biotech company developing gene therapies for rare childhood diseases. Its stock price is driven by news from its clinical trials. The chart reflects investor confidence in the potential of its platform for creating breakthrough drugs.
Share prices of companies in the market segment - Dna
Rocket Pharmaceuticals is a biotech company focused on gene therapy for rare pediatric diseases such as Fanconi anemia and leukocyte adhesion deficiency. We've classified it in the "Dna" segment. The chart below illustrates the overall dynamics of the gene therapy sector, where advances can dramatically change patients' lives, but the risks are very high.
Broad Market Index - GURU.Markets
Rocket Pharmaceuticals is a biotech company developing gene therapies to treat rare and devastating childhood diseases. As a component of the GURU.Markets index, it represents the cutting edge of medicine. The chart below represents the entire market. See how this innovator compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
RCKT - Daily change in the company's share price Rocket Pharmaceuticals
Change_co for Rocket Pharmaceuticals, a gene therapy company, reflects extreme volatility associated with clinical trial results. Daily fluctuations indicate sensitivity to news about the company's drug development. This metric is important for analyzing biotech breakthroughs on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Dna
Rocket Pharmaceuticals, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with RCKT, which focuses on gene therapy, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Rocket Pharmaceuticals is a biopharmaceutical company specializing in gene therapy for rare diseases. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with Rocket's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Rocket Pharmaceuticals
Rocket Pharmaceuticals' year-to-date performance is a story about developing gene therapy for rare childhood diseases. Its 12-month market cap depends entirely on clinical trial results and regulatory decisions. Every successful treatment and step toward FDA approval fundamentally changes the company's outlook, which is focused on saving lives.
Annual dynamics of market capitalization of the market segment - Dna
Rocket Pharmaceuticals, Inc. is a late-stage biotech company developing gene therapies for rare pediatric diseases. Its stock price reflects the enormous potential of its drugs and the regulatory risks associated with bringing this cutting-edge technology to market.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Rocket Pharma, a pioneer in gene therapy, is a high-risk, high-potential story. Its stock performance depends entirely on clinical trial results. The chart isn't about economics, but rather whether investors believe its revolutionary approach will become a new standard in treating rare diseases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Rocket Pharmaceuticals
The performance of Rocket Pharma, a gene therapy company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials and regulatory approvals for its drugs for rare pediatric diseases.
Monthly dynamics of market capitalization of the market segment - Dna
Rocket Pharmaceuticals is a company developing gene therapy for rare childhood diseases. Its success depends entirely on clinical trial results and regulatory approval. The gene therapy sector chart clearly demonstrates how willing investors are to invest in breakthrough, yet high-risk, technologies that could change patients' lives.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Rocket Pharmaceuticals is a leader in gene therapy for rare pediatric diseases. The company's shares move in sync with news about clinical trials and FDA decisions. Monthly performance barely correlates with the market, as investors evaluate the life-saving potential and future revenues of unique drugs rather than the economics.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Rocket Pharmaceuticals
Rocket Pharmaceuticals, a company developing gene therapy for rare childhood diseases, operates at the forefront of medicine. Its weekly stock price is a direct response to clinical trial results and regulatory decisions, where a single piece of news can radically change the entire investment story.
Weekly dynamics of market capitalization of the market segment - Dna
Biotech companies developing gene therapy, like Rocket Pharmaceuticals, are at the forefront of science. News in this field often impacts the entire industry. The chart below illustrates this general sentiment. It allows one to assess how promising the market perceives Rocket's platform compared to competitors' technologies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Rocket Pharmaceuticals is a leader in gene therapy for rare pediatric diseases. Its shares are a bet on the success of its cutting-edge scientific research. The chart clearly shows that the company's stock is driven by trial news, not by the market.
Market capitalization of the company, segment and market as a whole
RCKT - Market capitalization of the company Rocket Pharmaceuticals
Rocket Pharmaceuticals' market capitalization chart reflects the market's valuation of its cutting-edge gene therapy platform for rare pediatric diseases. Its performance reflects investors' belief that its approach, which uses viruses to deliver the "right" genes, can cure devastating diseases. Its high valuation is a bet on the potential for a complete cure.
RCKT - Share of the company's market capitalization Rocket Pharmaceuticals within the market segment - Dna
Rocket Pharmaceuticals is a leader in gene therapy for rare pediatric diseases. In the cutting-edge DNA medicine segment, its market capitalization reflects investor expectations for its pipeline. Its growth signals progress in clinical trials and the company's developments are getting closer to saving lives.
Market capitalization of the market segment - Dna
Here's a chart showing the combined weight of the entire biotech sector specializing in gene therapy. For Rocket Pharmaceuticals, a leader in treating rare childhood diseases, this line represents a sign of hope. Its growth represents an influx of capital into technologies capable of correcting genetic errors, enabling the company to conduct costly, life-saving research.
Market capitalization of all companies included in a broad market index - GURU.Markets
Rocket Pharmaceuticals is a leader in developing gene therapies for rare pediatric diseases. Its market capitalization represents enormous hope for a cure for diseases previously considered death sentences. This represents the share of the overall market that investors are investing in saving children's lives.
Book value capitalization of the company, segment and market as a whole
RCKT - Book value capitalization of the company Rocket Pharmaceuticals
Rocket Pharmaceuticals is a leader in gene therapy for rare pediatric diseases. Its book value is determined by its financial resources and production base: cash for trials and its own vector production capacity. How has this foundation of hope grown? The chart below shows this dynamic.
RCKT - Share of the company's book capitalization Rocket Pharmaceuticals within the market segment - Dna
Rocket Pharmaceuticals is a leader in gene therapy for rare diseases. Its breakthrough treatments require sophisticated infrastructure: its own, fully integrated manufacturing and laboratory facilities. The chart shows the significant share of the physical plant it is building for gene therapy production.
Market segment balance sheet capitalization - Dna
Rocket Pharmaceuticals, a gene therapy company, is a capital-intensive business. This requires owning cutting-edge manufacturing facilities. The BCap_Seg chart for the biotech sector shows that developing breakthrough technologies requires a robust and controlled resource base.
Book value of all companies included in the broad market index - GURU.Markets
Rocket Pharmaceuticals' assets aren't machine tools, but cutting-edge science embodied in its gene therapy platform and patent portfolio. Its book value reflects its massive investment in research and clinical development. The chart below shows how this science-intensive asset stacks up against traditional pharma.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Rocket Pharmaceuticals
Rocket Pharma's balance sheet is its R&D capital. Its entire enormous market value is a premium on its gene therapy platform, aimed at curing rare childhood diseases. Its earnings are a bet that its science will yield not just profits, but genuine miracles.
Market to book capitalization ratio in a market segment - Dna
Rocket Pharmaceuticals is a company developing gene therapies for rare pediatric diseases. Its high valuation on this chart reflects the huge unmet need for treatments for these diseases and the investors' faith in its scientific platform and team.
Market to book capitalization ratio for the market as a whole
Rocket Pharmaceuticals is a company developing gene therapies for rare childhood diseases. Its market capitalization is a bet on the future success of its clinical programs. This chart clearly demonstrates the vast gap between its book value and its market valuation, based on hope.
Debts of the company, segment and market as a whole
RCKT - Company debts Rocket Pharmaceuticals
Rocket Pharmaceuticals, a company developing gene therapies for rare pediatric diseases, is using capital to fund its expensive clinical programs and prepare for potential commercial launch. This chart shows how the biotech company is raising significant funds to advance its innovative, potentially life-saving treatments.
Market segment debts - Dna
Rocket Pharmaceuticals is a company developing gene therapy for rare pediatric diseases. This is a cutting-edge, but extremely expensive, field of medicine. Funding for such developments is almost always provided through equity. This chart clearly demonstrates how the company manages its enormous R&D costs without taking on debt.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Rocket Pharmaceuticals
Rocket Pharmaceuticals is developing gene therapies for rare diseases, which entails extremely high research costs. This chart shows the company's reliance on external funding. It illustrates a classic biotech dilemma: massive debt for the sake of a potential breakthrough that could change patients' lives and generate huge profits.
Market segment debt to market segment book capitalization - Dna
Rocket Pharmaceuticals is a company developing gene therapy for rare childhood diseases. Its mission is noble, but the road to drug approval is long and expensive. This chart shows how aggressively the biotech sector uses debt to finance breakthrough but risky developments, and where Rocket fits in this race.
Debt to book value of all companies in the market
Rocket Pharmaceuticals, a pioneer in gene therapy for rare diseases, is pursuing extremely expensive developments. This chart, reflecting the overall market leverage, allows one to assess the financial risks. It demonstrates how the company's R&D capital raising strategy aligns with the high standards and risks of the advanced biotech sector.
P/E of the company, segment and market as a whole
P/E - Rocket Pharmaceuticals
Rocket Pharmaceuticals is a biotech company developing gene therapies to treat rare and devastating childhood diseases. This chart shows how the market values its humanitarian mission and scientific potential. This assessment depends on the success of clinical trials and the potential of its drugs to bring hope to patients.
P/E of the market segment - Dna
Rocket Pharmaceuticals develops gene therapies for rare childhood diseases. This chart shows the average valuation for the biotech sector. It emphasizes that Rocket's valuation is based on the highest expectations for its scientific platform and the potential to cure devastating diseases, not on current profits.
P/E of the market as a whole
Rocket Pharmaceuticals is a biopharmaceutical company developing gene therapies to treat rare and devastating childhood diseases. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether RCKT's high valuation is based on faith in its breakthrough scientific platform or is driven by overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Rocket Pharmaceuticals
Rocket Pharmaceuticals is a company focused on gene therapy for rare pediatric diseases. Future profits depend on the success of its clinical programs and drug approvals. This chart reflects investors' high expectations that its cutting-edge treatments will transform patients' lives and lead to commercial success.
%20P%2FE%20Rocket%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Rocket-Pharmaceuticals&v=1772639679156 "Chart of the company's future (projected) P/E Rocket Pharmaceuticals")
Future (projected) P/E of the market segment - Dna
Rocket Pharmaceuticals is a company specializing in gene therapy for rare and devastating childhood diseases. The data here reflects the collective bet of analysts on the success of its clinical programs. It's a barometer of hope that its drugs will offer a cure or significant improvement for patients with limited treatment options.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772639679213 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Rocket Pharmaceuticals is developing gene therapies for rare childhood diseases. Their work has enormous humanitarian value. This sentiment chart shows how willing investors are to support biotech companies whose mission is to treat devastating diseases, even if the commercial market for them is small.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772639679231 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Rocket Pharmaceuticals
Rocket Pharmaceuticals is a company developing gene therapy for rare pediatric diseases. This chart highlights the high valuation and enormous potential of its developments. It reflects investments in clinical programs, each of which has the potential to not only generate profits but also radically change the lives of patients with previously incurable diseases.
Profit of companies in the market segment - Dna
Rocket Pharmaceuticals is a biopharmaceutical company specializing in gene therapy for rare pediatric diseases. Its mission is to bring hope to patients with limited treatment options. Currently in the clinical stage, it exemplifies capital-intensive investments in cutting-edge science, where the success of a single drug can dramatically change the financial picture.
Overall market profit
Rocket Pharmaceuticals specializes in gene therapy for rare childhood diseases. Its success and value depend solely on the results of clinical trials. There is no direct link to economics. However, the market conditions, which are influenced by this schedule, determine how easy or difficult it will be for the company to raise hundreds of millions of dollars for its research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Rocket Pharmaceuticals
Rocket Pharmaceuticals is a gene therapy company focused on treating rare pediatric diseases. This chart reflects analysts' speculative expectations for future profits. The forecast is entirely dependent on the success of clinical trials and regulatory approval of their potentially curative drugs, which could dramatically change the lives of patients.
%20profit%20of%20the%20company%20Rocket%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Rocket-Pharmaceuticals&v=1772639679447 "Graph of future (projected) profit of the company Rocket Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Dna
Rocket Pharmaceuticals is a biotech company working at the forefront of gene therapy for rare pediatric diseases. The profitability projections for this sector, shown in the graph, reflect both the enormous potential and the risks. This chart provides context for assessing the potential breakthrough potential of Rocket's drugs, which offer potential cures.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772639679484 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Rocket Pharmaceuticals is a biopharmaceutical company focused on gene therapy for rare pediatric diseases. Its operations require significant, long-term investment. Investor appetite for funding such risky projects is highly dependent on overall market conditions. A positive outlook on this chart improves the company's chances of raising capital.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772639679510 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Rocket Pharmaceuticals
Rocket Pharmaceuticals is a company developing gene therapies for rare pediatric diseases. It may not have commercial revenue. This chart shows the enormous value investors place on its research portfolio. The high valuation reflects the hope that its treatments, which target the underlying cause of the disease, will be successful.
P/S market segment - Dna
Rocket Pharmaceuticals is a biotech company specializing in gene therapy for rare and devastating childhood diseases. This metric reflects the average revenue estimate for the sector and helps understand how investors view the company's potential to transform the lives of patients with orphan diseases.
P/S of the market as a whole
Rocket Pharmaceuticals is a late-stage gene therapy company focused on treating rare pediatric diseases. The company has several promising programs in development. This chart helps compare how the market values companies based on current revenue, which is important for contextualizing biotech companies nearing commercialization.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Rocket Pharmaceuticals
Rocket Pharmaceuticals is a company specializing in gene therapy for rare pediatric diseases. This chart reflects investors' high valuation of its potential future revenue. This valuation is based on their belief in its scientific platform and ability to bring life-changing treatments to market.
%20P%2FS%20Rocket%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Rocket-Pharmaceuticals&v=1772639679754 "The graph of the company's future (projected) P/S Rocket Pharmaceuticals")
Future (projected) P/S of the market segment - Dna
Rocket Pharmaceuticals is a biotech company focused on gene therapy for rare pediatric diseases. This chart compares market expectations for its future revenue with other companies in the DNA technology sector. The valuation reflects investor confidence in its ability to bring life-saving treatments to market and their commercial potential.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772639679893 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Rocket Pharmaceuticals is a biotech company specializing in gene therapy for rare pediatric diseases. Its valuation is based on the potential of its drugs to transform patients' lives. This graph of overall market expectations is irrelevant to Rocket, as its success is determined by scientific breakthroughs and regulatory approvals, not economic cycles.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772639679907 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Rocket Pharmaceuticals
This chart illustrates the revenue of Rocket Pharmaceuticals, a company specializing in gene therapy for rare pediatric diseases. Being in the clinical stage, the company has no commercial revenue. A chart showing zero or negligible revenue is normal. Its value lies in its pipeline of drugs in development and the hope of their future approval and commercial success.
Sales of companies in the market segment - Dna
Rocket Pharmaceuticals is a late-stage biopharmaceutical company specializing in gene therapy for rare and devastating childhood diseases. This chart shows revenue in the DNA therapy sector. It reflects the promise of gene medicine and the potential for a one-time treatment to transform the lives of patients with previously incurable diseases.
Overall market sales
Rocket Pharmaceuticals is a company developing gene therapy for rare pediatric diseases. Its value is determined by success in clinical development. The overall economic situation shown in this chart does not directly affect demand, but it does influence the investment climate in the biotech sector and the future ability of healthcare systems to pay for expensive treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Rocket Pharmaceuticals
Rocket Pharmaceuticals is a clinical-stage gene therapy company focused on treating rare and devastating childhood diseases. This projected revenue chart reflects the high expectations for its science. The growth is driven by expectations for successful clinical trial results and potential approval of its life-changing drugs.
%20sales%20of%20the%20company%20Rocket%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Rocket-Pharmaceuticals&v=1772639680163 "Schedule of future (projected) sales of the company Rocket Pharmaceuticals")
Future (projected) sales of companies in the market segment - Dna
Rocket Pharmaceuticals is a clinical-stage gene therapy company focused on treating rare and devastating childhood diseases. Their approach is to correct the genetic cause of the disease. This chart shows projected revenue for the entire DNA therapy sector, reflecting the hopes associated with treating previously untreatable genetic disorders.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772639680203 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Rocket Pharmaceuticals is a gene therapy company for rare pediatric diseases. Its future depends on scientific breakthroughs and regulatory approvals. The overall economic climate and investor sentiment impact its ability to fund expensive research that could save patients' lives.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772639680223 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Rocket Pharmaceuticals
Rocket Pharmaceuticals is a leader in gene therapy for rare pediatric diseases. The company is at the forefront of science, which requires significant investment. This chart illustrates the cost of its mission: it reflects the investment in clinical trials and manufacturing required to bring potentially life-saving drugs to market.
Market segment marginality - Dna
Rocket Pharmaceuticals is a biotech company specializing in gene therapy for rare pediatric diseases. This chart shows its financial performance in the context of the industry. For a company in the development stage, outperforming competitors in profitability can be attributed to upfront payments from major pharmaceutical partners.
Market marginality as a whole
Rocket Pharmaceuticals is a biotech company specializing in gene therapy for rare pediatric diseases. Its success and value are independent of the general economic cycles shown in this chart. Progress in clinical trials is key. The approval of even one drug can completely transform the company and the lives of patients.
Employees in the company, segment and market as a whole
Number of employees in the company Rocket Pharmaceuticals
Rocket Pharmaceuticals is a leader in gene therapy for rare pediatric diseases. This chart shows its growing team of scientists and clinicians. This staff increase directly reflects progress in its clinical programs and investments in building its own manufacturing facilities, which are critical for gene therapy.
Share of the company's employees Rocket Pharmaceuticals within the market segment - Dna
Rocket Pharmaceuticals is a biotech company focused on gene therapy for rare pediatric diseases. Developing and manufacturing such complex treatments requires an elite team of scientists and manufacturing specialists. This chart shows the company's talent pool, reflecting its share of the pool of specialists working at the forefront of genetic medicine.
Number of employees in the market segment - Dna
Rocket Pharmaceuticals is a gene therapy company for rare childhood diseases. This chart illustrates the promise and complexity of this cutting-edge field of medicine. The growth of its scientific and clinical staff is directly linked to progress in clinical trials, which could offer a potential cure for patients with devastating genetic diseases.
Number of employees in the market as a whole
Rocket Pharmaceuticals is a biotech company developing gene therapy for rare pediatric diseases. Its growing staff is a team of scientists and physicians working at the cutting edge of science. This chart contrasts overall employment with the world of high-tech biotechnology, where job creation is directly linked to scientific progress and patient expectations.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Rocket Pharmaceuticals (RCKT)
Rocket Pharmaceuticals is a leader in gene therapy for rare pediatric diseases. The company's focus is on cures, not just symptomatic treatments. This chart shows its enormous market value per employee. This reflects investors' belief that the company's breakthrough science can lead to the creation of drugs with enormous value for society and shareholders.
%20of%20the%20company%20Rocket%20Pharmaceuticals%20(RCKT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Rocket-Pharmaceuticals-RCKT&v=1772639680512 "Chart of market capitalization per employee (in thousands of dollars) of the company Rocket Pharmaceuticals (RCKT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Rocket Pharmaceuticals is a biotech company specializing in gene therapy for rare pediatric diseases. In this cutting-edge and socially significant field, this figure reflects the high expectations of investors. The high cost per employee suggests that the market sees potential for a complete cure for serious diseases in the developments of their scientific team.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772639680540 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Rocket Pharmaceuticals is developing gene therapy for rare childhood diseases. This metric clearly illustrates the biotech model: market capitalization reflects not current revenue, but the potential value of a single drug. This allows a small research team to achieve a huge market valuation based on hope and science.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772639680556 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Rocket Pharmaceuticals (RCKT)
Rocket Pharmaceuticals is a biotech company specializing in gene therapy for rare pediatric diseases. They are in the clinical stage and are not profitable. This graph shows the loss per employee. This reflects the enormous cost of R&D in gene therapy, where each patient is a complex, individual project.
%20Chart%20Rocket%20Pharmaceuticals%20(RCKT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Rocket-Pharmaceuticals-RCKT&v=1772639680607 "Company Profit Per Employee (in thousands of dollars) Chart Rocket Pharmaceuticals (RCKT)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Rocket Pharmaceuticals is a biotech company developing gene therapies for rare, devastating diseases. The company is unprofitable, and gene therapy research is extremely expensive. This metric reflects their high burn rate on their R&D budget per employee, which is typical for this cutting-edge but capital-intensive field of medicine.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772639680633 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Rocket Pharmaceuticals is a biotech company specializing in gene therapy for rare childhood diseases. This is one of the most complex and expensive areas of medicine. This graph shows huge negative values—the colossal costs of each scientist and doctor required to develop breakthrough, but unique, treatments.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772639680663 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Rocket Pharmaceuticals (RCKT)
Rocket Pharmaceuticals is a biotech company specializing in gene therapy for rare pediatric diseases. This chart shows the company's business in the clinical development stage. Zero revenue per employee is normal for a company whose value is determined by the potential of its breakthrough treatments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Rocket-Pharmaceuticals-RCKT&v=1772639680696 "Sales chart per company employee Rocket Pharmaceuticals (RCKT)")
Sales per employee in the market segment - Dna
Rocket Pharmaceuticals (RCKT) is a biotech company specializing in gene therapy for rare (orphan) pediatric diseases. This chart shows how much revenue (from partnerships) each employee (scientist) generates. This is an indicator of the productivity of their R&D platform in one of the most complex and expensive areas of medicine compared to other gene therapy companies.
Sales per employee for the market as a whole
Rocket Pharmaceuticals is a biopharmaceutical company specializing in gene therapy for rare pediatric diseases. This is a highly complex R&D project. The company does not yet have commercial products. This metric does not reflect current performance. Any revenue currently generated likely comes from grants or partnerships, not sales.
Short shares by company, segment and market as a whole
Shares shorted by company Rocket Pharmaceuticals (RCKT)
Rocket Pharmaceuticals is a biotech company specializing in gene therapy for rare pediatric diseases. This chart reflects bearish sentiment. Bears point to the extremely high complexity and cost of producing gene therapies, as well as the binary risks of clinical trials, where a single failure can be fatal.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Rocket-Pharmaceuticals-RCKT&v=1772639680791 "Short Shares Chart for the Company Rocket Pharmaceuticals (RCKT)")
Shares shorted by market segment - Dna
Rocket Pharmaceuticals is a biotech company developing gene therapies to treat rare and devastating childhood diseases. This indicator reflects skepticism. The "short" here represents a bet that their complex treatments will not prove safe or effective in clinical trials.
Shares shorted by the overall market
Rocket Pharmaceuticals is a company developing gene therapy for rare childhood diseases. It's at the cutting edge of science, where every success is a breakthrough. This chart shows the overall level of market pessimism. When investors flee risk en masse, biotech stocks, especially those in complex fields, often come under severe pressure.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Rocket Pharmaceuticals (RCKT)
Rocket Pharmaceuticals develops gene therapies for rare childhood diseases. Its shares are highly volatile and dependent on R&D and FDA decisions. A chart above 70 may reflect positive FDA news or trial data. A chart below 30 is often associated with regulatory delays or setbacks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Rocket-Pharmaceuticals-RCKT&v=1772639680866 "RSI 14 indicator chart for the company's stock Rocket Pharmaceuticals (RCKT)")
RSI 14 Market Segment - Dna
Rocket (RCKT) — "CAR-T" and *gene therapy*. They *reprogram* (engineer) a patient's *stem cells* to treat rare *genetic* diseases. RSI_14_Seg for "Dna" (biotech) shows the overall sentiment in the sector. The chart helps us understand: is RCKT's volatility due to their R&D, or is the entire sector overheated?
RSI 14 for the overall market
Rocket Pharma (RCKT) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RCKT (Rocket Pharmaceuticals)
Rocket Pharma (RCKT) is a biotech company developing gene therapies for rare pediatric genetic diseases. This chart shows the average target price. It reflects analysts' belief in the breakthrough potential of its drugs and their expectations for FDA approval and commercial launch.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RCKT-Rocket-Pharmaceuticals&v=1772639680934 "A chart showing analyst consensus forecasts for the expected stock price. RCKT (Rocket Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price RCKT (Rocket Pharmaceuticals)
Rocket Pharma is a biotech company focused on gene therapy for rare, often fatal childhood diseases. Their R&D pipeline is focused on a one-time treatment. This graph reflects analysts' high, yet speculative, expectations regarding their clinical data and the ability to commercialize this highly complex therapy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RCKT-Rocket-Pharmaceuticals&v=1772639680945 "A chart showing the difference between the consensus forecast and the actual stock price. RCKT (Rocket Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Dna
Rocket Pharmaceuticals (RCKT) is a biotech company developing viral-based gene therapy for the treatment of rare childhood genetic diseases. This chart shows analysts' overall expectations for the DNA technology sector. It reflects whether experts believe the treatment for orphan diseases will be commercially successful.
Analysts' consensus forecast for the overall market share price
Rocket Pharmaceuticals (RCKT) is a company focused on gene therapy for rare, devastating childhood diseases. They develop one-shot treatments that target the root cause of the disease. This chart shows the overall risk appetite in the market, reflecting the willingness of investors to fund capital-intensive biotech breakthroughs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Rocket Pharmaceuticals
Rocket Pharma is a biotech company at the forefront of gene therapy. Their specialty is in-vivo (injection) and ex-vivo (cell) treatments for rare pediatric genetic diseases. This chart represents pure R&D betting. It likely reflects the market's confidence in their scientific platform (AAV and Lentiviral), their progress in clinical trials, and their manufacturing know-how.
AKIMA Market Segment Index - Dna
Rocket Pharma (RCKT) is a biotech leader in gene therapy; the company (like Sarepta) is developing a portfolio of breakthrough AAV-based drugs for the treatment of rare, fatal childhood diseases. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this breakthrough (R&D platform) model (RCKT) differentiate it from the average pharma company?
The AKIM Index for the overall market
Rocket Pharmaceuticals is a biotech company developing gene therapies for rare and devastating childhood diseases (Danone syndrome, LAD-I). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this mission-driven scientific story compares to the broader economic trends impacting complex treatments.
